Lausanne, Switzerland
Lausanne, Switzerland

Time filter

Source Type

Patent
Aurigene Discovery Technologies Ltd. and Debiopharm S.A. | Date: 2011-02-17

The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2010.2.4.1-6 | Award Amount: 3.90M | Year: 2011

Pancreatic ductal adenocarcinoma (PDAC) causes 34000 deaths in the EU every year. Conventional cancer treatments have close to no impact on this disease. As a result, almost all patients diagnosed with PDAC develop metastases and eventually die. Given this poor outlook, the search for new therapeutics is mandatory. These will have to target relevant cancer pathways and be designed based on the available knowledge on the genetic alterations that characterize this malignancy. We propose to build a team composed of clinicians, translational cancer researchers, chemists, and two pharmaceutical enterprises, to synthesize and implement new drugs for PDAC. The focus of the participants in this project will be on pathways and cellular functions broadly involved in PDAC metastasis and immune escape. These drugs are meant to work through diverse and novel modes of action and will be validated using genetically engineered PDAC mouse models that we have established at the Center for Integrated Oncology in Bonn. By creating and exploring diverse classes of compounds capable of arresting tumor growth and of interfering with its metastatic spread, this project will deliver a high number of new molecules with potential as anticancer therapeutics. In particular, our consortium will produce new indoleamine 2,3-dioxygenase-2 (IDO2) inhibitors, galectin-3 inhibitors, edelfosine analogues, inhibitors of the Hippo signaling pathway, alpha-mannosidase inhibitors, SIRT6 inhibitors, and therapeutics acting by synthetic lethality. For compounds with strong proof-of-concept activity, our consortium will perform the Investigational New Drug (IND)-Enabling Studies, with the goal of delivering a new drug ready to be tested clinically by the end of the project. The PANACREAS project is meant to help find better treatments for PDAC, boost research on this form of cancer in the EU, and open new avenues for scientific and technological innovation.


News Article | November 3, 2016
Site: www.prnewswire.co.uk

GenePOC, que está lista para comercializar su primera solución molecular para la identificación de Clostridium difficile en Europa, se complace anunciar que ha contratado a ocho socios de distribución para cubrir el mercado de Europa occidental. GenePOC, Inc. (GenePOC) ha anunciado que ha firmado acuerdos de distribución con ocho socios en Europa para la comercialización de sus primeros productos. Ese es un hito clave en el desarrollo de GenePOC y que cumple el plazo previsto por el programa y anunciado anteriormente de iniciar la comercialización en otoño de 2016. Los socios comerciales contratados son Astra Formedic S.r.l. en Italia, bestbion dx GmbH en Alemania/Austria, Biosynex Group en Francia, EMM Life Science AB en Suecia/Dinamarca/Finlandia/Noruega/Islandia, Fannin Ltd en Irlanda, Mediphos Group BV en Países Bajos/Bélgica/Luxembourgo, Near Patient Diagnostics Ltd en el Reino Unido, y Vitro S.A.B. de C.V. en España/Portugal. El conocimiento y posición de estos socios en el mercado, combinados con su dedicación, entusiasmo y confianza en GenePOC permitirán a la compañía abordar los próximos pasos clave en el camino al éxito comercial en las mejores condiciones posibles. Los socios de GenePOC tienen una fuerte posición en la enfermedad infecciosa, diagnóstico molecular y/o punto de atención, dando a GenePOC gran confianza para una entrada sólida y rápida expansión en el mercado europeo a través de estas colaboraciones. "Estamos encantados con las colaboraciones firmadas y el entusiasmo de nuestros Socios que experimentamos durante nuestro primer encuentro con los distribuidores con motivo del lanzamiento de productos que celebramos la primera semana de octubre", dijo Patrice Allibert, consejero delegado de GenePOC. GenePOC es una compañía especializada en el desarrollo de dispositivos de diagnóstico rápido que permiten la prevención y detección de enfermedades infecciosas. GenePOC es un miembro (de propiedad mayoritaria) de Debiopharm Group. La compañía diseñó el sistema GenePOC Diagnostics, que permite las pruebas microbiales rápidas en el punto de atención (POC, por sus siglas en inglés). Este instrumento puede analizar cualquier tipo de infección en menos de una hora, es fácil de operar con un amplio rango de muestras biológicas, haciéndolo una herramienta sencilla para el usuario y eficiente. En 2013, Frost & Sullivan reconoció a GenePOC en la categoría Compañía Norteamericana del Año en Diagnóstico Molecular en el 2013 Best Practices Award 2013. Debiopharm Group™ es un grupo farmacéutico global con sede en Suiza formado por cinco compañías activas en desarrollo de fármacos, fabricación de fármacos y herramientas de diagnóstico. Debiopharm se centra en el desarrollo de fármacos de prescripción que se orientan a las necesidades médicas no cubiertas. La compañía obtiene licencias y desarrolla candidatos a fármacos prometedores. Los productos se comercializan por socios farmacéuticos que otorgan licencias para dar acceso al mayor número de pacientes en el mundo. Estamos en Twitter. Siga a @DebiopharmNews en http://twitter.com/DebiopharmNews Contacto de Debiopharm International SA Christelle Tur Coordinadora de Comunicaciones christelle.tur@debiopharm.com Tel.: +41(0)21-321-01-11 Contacto en GenePOC Patrice Allibert Consejero delegado patrice.allibert@genepoc.ca  Tel.: +1-418-650-3535


GenePOC, which is ready to commercialize its first molecular solution for Clostridium difficile identification in Europe, is proud to announce that it has signed 8 distribution partners to cover the Western European market. GenePOC, Inc. (GenePOC) has announced that it signed distribution agreements with 8 partners across Europe for the commercialization of its first products. This is a key Milestone in the development of GenePOC and the timing fits well with the timeline announced earlier to start commercialization in autumn of 2016. The commercial partners signed up are Astra Formedic S.r.l.in Italy, bestbion dx GmbH in Germany/Austria, Biosynex Group in France, EMM Life Science AB in Sweden/Denmark/Finland/Norway/Iceland, Fannin Ltd in Ireland, Mediphos Group BV in Netherlands/Belgium/Luxembourg, Near Patient Diagnostics Ltd in the UK and Vitro S.A.B. de C.V. in Spain/Portugal. The knowledge and position of these partners in the market combined with their dedication, enthusiasm and confidence in GenePOC will allow the company to tackle the next key steps on the road to commercial success in the best possible conditions. GenePOC's partners have a strong position in infectious disease, molecular diagnostics and/or Point-of-care, giving GenePOC great confidence for a solid entry and rapid expansion into the European Market through these collaborations. "We are delighted with the collaborations signed and the enthusiasm of our Partners that we experienced during our first distributors' meeting in preparation for product launch that we held in the first week of October," said Patrice Allibert CEO of GenePOC. GenePOC is a company that specializes in the development of rapid diagnostic devices which enable the prevention and detection of infectious diseases. GenePOC is a member (majority owned) of the Debiopharm Group. The company devised the GenePOC Diagnostics system, enabling rapid microbial testing at the point of care (POC). This instrument can analyses any type of infection in no more than an hour, is easy to operate and deals with a wide range of biological samples, making it a user-friendly and efficient tool. In 2013, Frost & Sullivan recognized GenePOC by presenting it with the 2013 Best Practices Award North American Molecular Diagnostics Entrepreneurial Company of the Year. Debiopharm Group™ is a Swiss-headquartered global biopharmaceutical group of five companies active worldwide in the development and manufacture of drugs and diagnostic tools. Debiopharm focuses on developing prescription drugs and diagnostics that target unmet medical needs. The group in-licenses and develops promising drug candidates. The products are commercialized by out-licensing partners and distribution partners to give access to the largest number of patients worldwide. For more information, please see http://www.debiopharm.com We are on Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews


GenePOC, qui s'apprête à débuter en Europe la commercialisation de sa première solution moléculaire pour l'identification de Clostridium difficile, est fière d'annoncer la signature de 8 accords de distribution visant à couvrir le marché d'Europe de l'Ouest. GenePOC, Inc. (GenePOC) a annoncé avoir signé des accords de distribution avec 8 partenaires à travers l'Europe pour la commercialisation de ses premiers produits. Il s'agit là d'une étape clé dans le développement de GenePOC, qui s'inscrit parfaitement dans le calendrier annoncé précédemment, selon lequel la commercialisation devait débuter à l'automne 2016. Les partenaires commerciaux signataires des accords sont Astra Formedic S.r.l. en Italie, bestbion dx GmbH en Allemagne/Autriche, Biosynex Group en France, EMM Life Science AB en Suède/Danemark/Finlande/Norvège/Islande, Fannin Ltd. en Irlande, Mediphos Group BV aux Pays-Bas/Belgique/Luxembourg, Near Patient Diagnostics Ltd au Royaume-Uni et Vitro S.A.B. de C.V. en Espagne/Portugal. Le savoir-faire et la position de ces partenaires sur le marché, combinés à leur engagement, à leur enthousiasme et à la confiance qu'ils accordent à GenePOC, permettront à l'entreprise d'aborder dans les meilleures conditions possibles les prochaines étapes clés sur le chemin du succès commercial. Les partenaires de GenePOC bénéficient d'une solide position dans les domaines de l'identification des agents infectieux, des diagnostics moléculaires et/ou diagnostics sur le lieu des soins, ce qui permet à l'entreprise d'être extrêmement confiante quant à l'ampleur de sa pénétration et à la rapidité de son expansion sur le marché européen au travers de ces collaborations. « Nous sommes ravis des accords de collaboration que nous avons signés et de l'enthousiasme que nous avons constaté chez nos partenaires lors de notre première réunion préparatoire pour le lancement des produits, qui s'est tenue la première semaine d'octobre », a déclaré Patrice Allibert, Président et de la Direction de GenePOC. GenePOC est une entreprise spécialisée dans le développement de dispositifs de diagnostic rapide qui permettent de prévenir et de détecter les maladies infectieuses. GenePOC est membre de (appartient majoritairement à) Debiopharm Group. L'entreprise a mis au point le système GenePOC Diagnostics, qui permet d'effectuer des tests microbiens rapides sur les lieux des soins. Capable d'analyser tout type d'infection en une heure maximum, cet instrument est simple d'utilisation et traite un large éventail d'échantillons biologiques, ce qui en fait un outil convivial et efficace. En 2013, Frost & Sullivan a récompensé GenePOC en lui décernant le titre de « 2013 Best Practices Award North American Molecular Diagnostics Entrepreneurial Company of the Year ». Debiopharm Group™, dont le siège social principal se trouve en Suisse, est un groupe international de cinq sociétés biopharmaceutiques, actif mondialement dans les domaines du développement et de la fabrication de médicaments et d'outils de diagnostic. Debiopharm se concentre sur le développement de médicaments délivrés sur ordonnance et de diagnostiques ciblant des besoins médicaux non satisfaits. Le groupe acquiert des licences puis développe des médicaments candidats prometteurs. Les produits sont commercialisés par l'octroi de licences à des partenaires et des distributeurs, afin de les rendre accessibles au plus grand nombre possible de patients dans le monde. Nous sommes présents sur Twitter. Suivez-nous @DebiopharmNews à l'adresse http://twitter.com/DebiopharmNews Tél. : +41(0)21-321-01-11 Contact chez GenePOC Patrice Allibert Président et chef de la Direction patrice.allibert@genepoc.ca Tél. : +1-418-650-3535


Janssens S.,Ghent University | Tinel A.,Debiopharm SA
Cell Death and Differentiation | Year: 2012

P53-induced protein with a death domain (PIDD) was cloned as a death domain (DD)-containing protein whose expression is induced by p53. It was later described as the core of a molecular platform-activating caspase-2, named the PIDDosome. These first results pointed towards a role for PIDD in apoptosis, in response to DNA damage. Identification of new PIDDosome complexes involved in DNA repair and nuclear factor-κB signaling challenged this early concept. PIDD functions are growing as new complexes and new interaction partners are being discovered, and as additional functions are being revealed. A fascinating feature of PIDD lies within its complex and tight regulation mechanisms, which allow the molecule to fine-tune its different functions: from transcriptional regulation to the expression of different isoforms, and from the interaction with regulatory proteins to an ingenious post-translational cleavage mechanism generating various active fragments with specific functions. Further studies still need to be carried out to provide answers to many unresolved issues and to reconcile conflicting results. This review aims at providing an overview of the current PIDD knowledge status. © 2012 Macmillan Publishers Limited All rights reserved.


Patent
Catholic University of Leuven and Debiopharm SA | Date: 2013-12-23

Assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.


Patent
Debiopharm S.A. | Date: 2014-08-27

The present invention relates to an indole derivative of structural formula (I), or a pharmaceutically acceptable salt or solvate thereof, which is useful as a direct AMPK activator, to uses and methods of use thereof, and to pharmaceutical compositions comprising such compound.


Patent
Debiopharm S.A. and Novartis | Date: 2011-12-12

The invention provides lipid-based pharmaceutical compositions comprising alisporivir.


Patent
Novartis and Debiopharm S.A. | Date: 2016-05-12

The invention provides lipid-based pharmaceutical compositions comprising alisporivir.

Loading Debiopharm SA collaborators
Loading Debiopharm SA collaborators